The number of teenagers using weight loss medications is on the rise, influenced by the approval of Wegovy for adolescents as young as 12 and revised guidelines for treating childhood
Continue reading1 Rising Trend in Adolescent Obesity: Teenagers Turning to Weight Loss Medications
Semaglutide, a GLP-1 receptor agonist found in medications such as Ozempic, Rybelsus, and Wegovy, has been shown to provide significant benefits for long-term weight loss and cardiovascular health. Weight Loss
Continue readingSemaglutide has BOTH Weight Loss & Cardiovascular Health benefits
The SURMOUNT-4 phase 3 clinical trial, led by researchers at Weill Cornell Medicine and NewYork-Presbyterian, investigated the effectiveness of anti-obesity drugs, particularly tirzepatide, in maintaining weight loss over the long